Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 10

Complete if Known	
Application Number	10/698,099
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1648
Examiner Name	Michelle S. Horning
Attorney Docket Number	015270-008930US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-7,138,255	11-21-2006	Vodyanoy et al.	
	2	US-2006/0259986	11-16-2006	Chilcote et al.	
	3	US-2006/0058233	03-16-2006	Schenk et al.	
	6	US-2005/0196818	09-08-2005	Chilcote et al.	
	7	US-2005/0198694	09-08-2005	Chilcote et al.	
	8	US-2005/0176078	08-11-2005	Allsop et al.	
	13	US-2005/0037013	02-17-2005	Schenk et al.	
	19	US-6,780,971	08-24-2004	Wolozin et al.	
	20	US-2004/0146521	07-29-2004	Schenk et al.	
	21	US-2004/0137523	07-15-2004	Vodyanoy et al.	
	22	US-2004/0136993	07-15-2004	Schenk et al.	
	25	US-6,710,226	03-23-2004	Schenk	
	32	US-2002/0160394 A1	10-31-2002	Wu	
	37	US-5,589,154	12-31-1996	Anderson	
	38	US-5,576,184	11-19-1996	Better et al.	
	39	US-4,883,666	11-28-1989	Sabel et al	

U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	40	US-11/710,248	02-23-2007	Schenk et al.	
	41	US-11/697,646	04-06-2007	Schenk et al.	
	42	US-11/660,015	02-09-2007	Schenk et al.	
	43	US-10/850,570	05-19-2004	Chilcote et al.	
	44	US-60/518,140	11-08-2003	Chilcote et al.	
	45	US-60/471,929	05-19-2003	Chilcote et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	46	EP	0 613 007	A2	08-31-1994			☐
	47	WO	07/021255	A1	02-22-2007	Chilcote et al.		☐
	48	WO	07/012061	A2	01-25-2007	Schenk et al.		☐
	49	WO	06/045037	A2	04-27-2006	Chilcote et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/698,099
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	2	of	10	Attorney Docket Number	015270-008930US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (*if known*)				
	50	WO	06/045037	A3	04-27-2006	Chilcote et al.		☐
	51	WO	06/020581	A2 corrected version	02-23-2006	Schenk et al.		☐
	52	WO	06/020581	A3	02-23-2006	Schenk et al.		☐
	55	WO	05/047860	A3	05-26-2005	Chilcote et al.		☐
	57	WO	04/041067	A3	05-21-2004	Schenk et al.		☐
	59	WO	04/009625	A3	01-29-2004	El-Agnaf et al.		☐
	184	WO	01/053457	A3	07-26-2001	University of Connecticut Health Center		☐
	186	WO	01/06989	A3	02-01-2001	Abgenix, Inc.		☐
	61	WO	00/72880	A3	12-07-2000	Schenk et al.		☐
	63	WO	00/072876	A3	12-07-2000	Schenk		☐
	64	WO	00/18917	A2 corrected version	04-06-2000	Amgen Inc.		☐
	65	WO	00/18917	A3 corrected version	04-06-2000	Amgen Inc.		☐
	67	WO	99/050300	A1	10-07-1999	Trojanowski et al.		☐
	71	WO	99/006545	A2 corrected version	02-11-1999	Max Plank Institute		☐
	72	WO	99/006545	A3 corrected version	02-11-1999	Max Plank Institute		☐
	73	WO	95/006407	A1	03-09-1995	Masliah		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				*Examiner Name*	Michelle S. Horning
Sheet	3	of	10	*Attorney Docket Number*	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	75	ABBAS et al., Cellular and Molecular Immunology, 522-523 (Elsevier Saunders) (5th Ed. Updated Ed., 2005).	☐
	76	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody," J. Clin. Invest., 116(3):825-832 (2006).	☐
	187	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000).	☐
	77	BENNETT et al., "Degradation of α-Synuclein by Proteasome," J. Biol. Chem., 274(48):33855-33858 (1999).	☐
	78	BROOKS et al., "Synuclein proteins and Alzheimer's disease," Trends Neurosci., 17(10):404-405 (1994).	☐
	80	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," Progress in Brain Research, 117:327-337 (1998).	☐
	81	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," J. Neurosci. Res., 58:120-129 (1999).	☐
	82	CLAYTON et al, "The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease," Trends Neurosci., 21(6):249-254 (1998).	☐
	83	CLELAND et al., "Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21," J.of Pharm Sci., 85(1): 22-28 (1996).	☐
	85	CROWTHER et al., "Synthetic filaments assembled from C-terminally truncated a-synuclein," FEBS Letters, 436:309-312 (1998).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	4	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	88	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	☐
	90	DI MONTE et al., "Environmental Factors in Parkinson's Disease," Neurotoxicology, 23: 487-502 (2002).	☐
	191	DIXON, C. et al., "Alpha-Synuclein Targets the Plasma Membrane via the Secretory Pathway and Induces Toxicity in Yeast," Genetics, 2005 May;170(1):47-59. Epub 2005 Mar 2.	☐
	178	EL-AGNAF et al., "α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma," FASEB J., 17(3):1945-1947 (2003).	☐
	91	EL-AGNAF et al., "α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma," FASEB J. express article 10.1096/fj.03-0098fje, Published online August 15, 2003.	☐
	94	ELIEZER, D. et al., "Conformational Properties of Alpha-Synuclein in its Free and Lipid-associated States," Journal of Molecular Biology, 307(4):1061-1073 (2001).	☐
	95	ELLIS et al., "α-Synuclein is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases," J. Biol. Chem., 276(6):3879-3884 (2001).	☐
	96	EMADI, S. et al., "Inhibiting Aggregation of Alpha-Synuclein with Human Single Chain Antibody Fragments," Biochemistry, 43(10):2871-2878 (2004).	☐
	98	EP 04776059.0 European Supplementary Search Report completed 06/13/2006.	☐
	192	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science, 920:274-284 (2000).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	5	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	193	GARZON, J. et al., "Transport of CSF antibodies to G-Alpha subunits across neural membranes requires binding to the target protein and protein kinase C activity," Molecular Brain Research, 65(2):151-166 (1999).	☐
	106	GIASSON et al., "Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies *in Vitro*," J. Biol. Chem., 274(12):7619-7622 (1999).	☐
	108	GOLDSTEINS et al., "Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999).	☐
	110	HAMBURGER, A.W. et al., "Isolation and characterization of monoclonal antibodies reactive with endothelial cells," Tissue & Cell, 17(4): 451-459 (1985).	☐
	112	HARTMAN et al., "Treatment with an Amyloid-β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease," Journal of Neuroscience, 25:6213-6220 (2005).	☐
	113	HOOPER et al., Cellular Peptidases in Immune Functions and Diseases 2, (Langer and Ansorge, Eds., Plenum Publishers) 379-390 (2000).	☐
	114	HOYER, W. et al., "Dependence of alpha-Synuclein Aggregate Morphology on Solution Conditions," J. Mol. Biol., 322:383-393 (2002).	☐
	179	IWAI, "Properties of NACP/alpha-synuclein and its role in Alzheimer's disease," Molecular Basis of Disease, 1502(1): 95-109 (2000).	☐
	116	IWATSUBO, T. et al., "Purification and Characterization of Lewy Bodies from the Brains of Patients with Diffuse Lewy Body Disease," Am J Pathol., 148(5):1517-1529 (1996).	☐
	117	JAKES et al., "Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein," Neurosci. Ltrs., 269:13-16 (1999).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	6	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	120	KIM, T. D. et al., "Structural and Functional Implications of C-Terminal Regions of α-Synuclein," Biochemistry, 41:13782-13790 (2002).	☐
	121	KIM, T.D. et al., "Structural Changes in α-Synuclein Affect its Chaperone-like Activity in Vitro," Protein Science, 9:2489-2496 (2000).	☐
	123	KUBY J., eds., Immunology, pp. 92-97 and 131 (W.H. Freeman & Co., New York) (3rd Edition, 1997).	☐
	124	KUBY J., eds., Immunology, pp. 156-158 (W.H. Freeman & Co., New York) (3rd Edition, 1997).	☐
	199	LANSBURY JR., P. T., "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease," Proc Natl Acad Sci, 96(7): 3342–3344 (1999).	☐
	125	LEE et al., "Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors," J. Biol. Chem., 277(7):5411-5417 (2002).	☐
	126	LEE et al., "Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice," PNAS, 99:8968-8973 (2002).	☐
	200	LEMERE, C. A. et al., Amyloid-Beta Immunization in Alzheimer's Disease Transgenic Mouse Models and Wildtype Mice," Neurochem Res., 28(7):1017-27.2003).	☐
	201	LUTHI-CARTER, R., "Progress towards a Vaccine for Huntington's Disease," Mol Ther,. 7(5, Pt 1):569-70 (2003).	☐
	203	MCLEAN, et al., "Membrane Association and Protein Conformation of Alpha-Synuclein in Intact Neurons," J Biol Chem., 275(12):8812-6 (2000).	☐
	133	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	7	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	134	MISHIZEN-EBERZ et al., "Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I *in vitro*," J. Neurochemistry, 86:836-847 (2003).	☐
	204	MORGAN, et al., "Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature, 408(6815):982-5 (2000).	☐
	136	OKOCHI, M. "Constitutive Phosphorylation of the Parkinson's Disease Assocated α-Synuclein," J. Biol. Chem., 275(1): 390-397 (2000).	☐
	137	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " J. Mol. Med., 78:703-707 (2001).	☐
	138	PCT/US05/37875 International Preliminary Report on Patentability Chapter 1 issued 04/24/2007 with Written Opinion	☐
	139	PCT/US05/28166 International Preliminary Report on Patentability Chapter 1 issued 02/13/2007 with Written Opinion	☐
	140	PCT/US04/37444 International Preliminary Report on Patentability Chapter 1 issued 06/19/2007 with Written Opinion	☐
	141	PCT/US04/015836 International Preliminary Report on Patentability Chapter 1 issued 11/25/2005 with Written Opinion	☐
	142	PCT/US00/015239 International Preliminary Examination Report dated 08/13/2001	☐
	145	QUE et al., "Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines against Plasmodium falciparum Circumsporozoites," Infection and Immunity, 56(10): 2645-2649 (1988).	☐
	147	SCHENK, D., "Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning," Nature Reviews, 3:824-828 (2002).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	8	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	149	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," American Journal of Pathology, 161:13-17 (2002).	☐
	150	SIGURDSSON et al., "Anti-prion antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003).	☐
	151	SIPE, "Amyloidosis," Annu. Rev. Biochem., 61:947-975 (1992).	☐
	152	SKIPPER et al., "Parkinson's Genetics: molecular Insights for the New Millennium," Neurotoxicology, 23: 503-514 (2002).	☐
	155	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," PNAS, 97(11):6037-6042 (2000).	☐
	156	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS, 93:452-455 (1996).	☐
	157	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," Expert Opin. Biol. Ther., 2(8):907-917 (2002).	☐
	159	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (2002).	☐
	160	SU et al., "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," Brain Research, 818:105-107 (1999).	☐
	161	TAKAHASHI, M. "Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila," Neuroscience Letters, 336: 155-158 (2003).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				Examiner Name	Michelle S. Horning
Sheet	9	of	10	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	180	TAKEDA et al., "Abnormal Distribution of the Non-Aβ Component of Alzheimer's Disease Amyloid Precursor/alpha-synuclein in Lewy Body Disease as Revealed by Proteinase K and Fromic Acid Pretreatment," Laboratory Investigation, 79(9):1169-1177 (1998).	☐
	162	TAKEDA, A. et al., "C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders," Acta Neuropathol, 99:296-304 (2000).	☐
	163	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," Journal of Neuroscience Research, 71:286-290 (2003).	☐
	164	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).	☐
	165	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995).	☐
	166	TSIM, K.W. et al., "Monoclonal antibodies specific for the different subunits of asymmetric acetylcholinesterase from chick muscle," J. Neurochem., 51(1):95-104 (1988).	☐
	207	UBOL et al., "Roles of Immunoglobulin Valency and the Heavy-Chain Constant Domain in Antibody-Mediated Downregulation of Sindbis Virus Replication in Persistently Infected Neurons," J Virol., 1995 March; 69(3): 1990–1993.	☐
	172	WALKER et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).	☐
	173	WATSON et al., "Chapter 14: The Introduction of Foreign Genes into Mice," Molecular Biology of Watson Recombinant DNAs, 2nd ed., 255-272 (1993).	☐
	174	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," Biochemistry, 35(43):13709-13715 (1996).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
(Use as many sheets as necessary)				*Examiner Name*	Michelle S. Horning
Sheet	10	of	10	*Attorney Docket Number*	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	175	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," Biochemical Society Transactions, 30(4):574-587 (2002).	☐
	210	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," PNAS, 82:8729-8732 (1985).	☐
	176	YOSHIMOTO et al., "NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation," PNAS, 92:9141-9145 (1995).	☐
	211	ZHOU et al., "A Human Single-Chain Fv Intrabody Blocks Aberrant Cellular Effects of Overexpressed alpha-Synuclein," Mol Ther., 10(6):1023-31 (2004).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.